Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OCEAN(a)-CCTA olpasiran plaque imaging trial
NL-OMON60555Phase 3Not yet recruiting
- Sponsor
- Amgen
- Start
- Mar 2026
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hyperlipoproteinemia comparing Olpasiran with Placebo (2 arms). Primary endpoint: Change in non-calcified plaque volume from baseline to week 72. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
olpasiran
03
Conditions
atherosclerotic diseasehyperlipoproteinemia
Beyond the preview
Go deeper on NL-OMON60555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60555.